The SMC recommends nivolumab–relatlimab for untreated, unresectable or metastatic melanoma in people 12 years and over

On the 8th July 2024, the Scottish Medicines Consortium (SMC) approved the recommendation of a new immunotherapy treatment nivolumab–relatlimab within NHS Scotland for untreated, advanced (unresectable or metastatic) melanoma in people 12 years and over. Melanoma Focus supported the application by undertaking a patient questionnaire and completing a Patient Group Submission.

Our CEO, Susanna Daniels commented:

“For patients, a diagnosis of advanced melanoma is often overwhelming. However, advances in immunotherapies can give hope to people living with this condition. This important milestone means that eligible patients in Scotland with advanced melanoma can now also potentially benefit from a novel immunotherapy combination treatment option.”

This treatment was approved for this indication by NICE [TA950] and published in February 2024.

For more information and to read the final draft guidance on the use of nivolumab-relatlimab, click here.